Tesaro's Varubi Wins FDA Approval; Shares Up
This article was originally published in Scrip
Executive Summary
Shares of Tesaro jumped about 10% on Sept. 2 on the news the FDA had approved the Waltham, MA firm's new drug application to market Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (CINV) in adults.
You may also be interested in...
US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing
Tesaro’s IV formulation of Varubi draws letter keeping with last year’s emerging trend of manufacturing-related CRLs, in this case agency concerns about CMC data related to comparability of drug produced by two different contractors; issue seems unlikely to significantly delay approval of the new version of CINV drug, however.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.